Abstract:Graphical Beneficial and harmful effects of IL22 in the intestine. IL‐22 is produced by various immune cells at the intestinal epithelium. Here, it acts on enterocytes by binding to the IL‐22 receptor complex to initiate its effects. These include inducing cell proliferation/tumorigenesis, wound healing, and induction of mucins by Goblet cells and antimicrobial peptides by Paneth cells. If produced in excessive amounts, these antimicrobial peptides may damage the intestinal epithelium and reduce microbial diversity. IL‐22 induces tight junction proteins, modulating epithelial barrier permeability. IL‐22 also induces Paneth cells differentiation in humans (image created with Biorender). Interleukin‐22 (IL‐22) is an important cytokine in the intestinal environment. IL‐22 is mainly produced by immune cells and targeted at nonimmune cells such as epithelial and stromal cells in a broad array of tissues such as ‐but not restricted to‐ the liver and adipose tissue. IL‐22 therefore connects immune functions with metabolic functions of the host, and since it is induced by the microbiota, connects host functioning to the outside environment. IL‐22 induces epithelial cell proliferation aiding in rapid epithelium regeneration and wound healing. Additionally, IL‐22 activates antiapoptotic genes and DNA damage response pathways, enhancing epithelial cell survival. Recently, it has also been shown that IL‐22 induces Paneth cell differentiation in humans. However, IL‐22 can also contribute to intestinal epithelium damage and reduces microbial diversity in the intestine directly or indirectly by inducing excessive antimicrobial peptide production by epithelial cells. Moreover, IL‐22 enhances angiogenesis and may therefore support tumorigenesis in the intestine. In conclusion, it appears that whether IL‐22 has a beneficial or harmful effect in the mammalian intestine largely depends on its regulation. This review aims to provide a comprehensive overview of the current literature and emphasizes that IL‐22 signaling outcome depends on the timing and duration of IL‐22 production, the presence of it regulators such as IL‐22BP, and the specific location of the cytokine production in the gastrointestinal tract.

Biological and Pathological Activities of Interleukin-22

Interleukin-22, a Potent Target for Treatment of Non-Autoimmune Diseases.

IL-22 as a target for therapeutic intervention: Current knowledge on its role in various diseases

Physiological and Pathological Properties of Interleukin-22 in Liver Diseases

Interleukin 22 in Liver Injury, Inflammation and Cancer

I don't know about you, but I'm feeling IL-22

IL-22, cell regeneration and autoimmunity

IL-22 Signaling in the Tumor Microenvironment

Role of Interleukin-22 in Inflammatory Bowel Disease.

Interleukin-22: A Likely Target for Treatment of Autoimmune Diseases

Interleukin‐22 and intestinal homeostasis: Protective or destructive?

Immunomodulation of Interleukin-34 and Its Potential Significance As a Disease Biomarker and Therapeutic Target

Interleukin-22 in allergic airway disease

Role of IL-22 in Intestinal Microenvironment and Potential Targeted Therapy Through Diet

The role of the IL-22/IL-22R1 axis in cancer

IL-22, a vital cytokine in autoimmune diseases

Emerging Role of Interleukin-22 in Autoimmune Diseases

Role of Interleukin-22 in ulcerative colitis

MicroRNAs: New Regulators of IL-22.

The role of IL-22 in cancer

The role of interleukin‐22 in mammalian intestinal homeostasis: Friend and foe